As markets face downturns due to tariff fears, inflation, and recession concerns, unique stock movements are observed. Regeneron Pharmaceuticals saw a 4% increase after reporting successful results from their ADEPT Phase 2/3 trial. The trial focused on the drug Dupixent for treating moderate-to-severe bullous pemphigoid. Meanwhile, Biogen's stock is also rising as it presents a value opportunity amidst overall market distress. Economics experts warn of shrinking growth due to consumer spending cuts and intensified recession risks, highlighting the fragility of the current economic landscape.
Given this is so uncertain and that there are new announcements every hour or so, it's kind of unclear what the environment is going to look like. It's hard to deny the risk of a recession has intensified.
There's a risk both in terms of higher inflation and downside for activity.
The ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent.
While we're not seeing any specific news, BIIB has become a value play.
Collection
[
|
...
]